Menu
Search
|

Menu

Close
X

Madrigal Pharmaceuticals Inc MDGL.OQ (NASDAQ Stock Exchange Capital Market)

143.72 USD
-- (--)
As of Nov 14
chart
Previous Close 143.72
Open --
Volume --
3m Avg Volume 81,087
Today’s High --
Today’s Low --
52 Week High 325.58
52 Week Low 39.06
Shares Outstanding (mil) 12.50
Market Capitalization (mil) 586.42
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 9 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-1.456
FY17
-2.541
FY16
-28.235
FY15
-13.038
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.64
Price to Sales (TTM)
vs sector
--
5.95
Price to Book (MRQ)
vs sector
9.52
4.89
Price to Cash Flow (TTM)
vs sector
--
22.90
Total Debt to Equity (MRQ)
vs sector
0.00
17.74
LT Debt to Equity (MRQ)
vs sector
0.00
13.15
Return on Investment (TTM)
vs sector
-70.04
14.22
Return on Equity (TTM)
vs sector
-70.04
15.99

EXECUTIVE LEADERSHIP

Paul Friedman
Chairman of the Board, Chief Executive Officer, Since 2016
Salary: $400,000.00
Bonus: $335,000.00
Marc Schneebaum
Chief Financial Officer, Senior Vice President, Since 2014
Salary: $365,000.00
Bonus: $244,500.00
Rebecca Taub
Chief Medical Officer, Executive Vice President - Research & Development and Director, Since 2016
Salary: $370,000.00
Bonus: $247,900.00
Frederick Craves
Lead Independent Director, Since 2016
Salary: --
Bonus: --
Kenneth Bate
Independent Director, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

200 Barr Harbor Dr Ste 400
CONSHOHOCKEN   PA   19428-2978

Phone: +1404.3809263

Madrigal Pharmaceuticals, Inc., formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company's lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH). Its product pipeline also includes MGL-3745, which is used in the treatment of NASH and FH. MGL-3196 has completed Phase I single and multiple dose trials in healthy volunteers. MGL-3196 is being developed for dyslipidemia/hypercholesterolemia to lower low-density lipoproteins cholesterol, triglyceride levels and lipoprotein(a). MGL-3196 also reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.

SPONSORED STORIES